Search hospitals > Ontario > HAMILTON
Hamilton General Hospital
Claim this profileHAMILTON, Ontario L8L 2X2
Global Leader in Atrial Fibrillation
Global Leader in Thrombus
Conducts research for Stroke
Conducts research for Heart Attack
Conducts research for Myocardial Infarction or Heart Attack
194 reported clinical trials
30 medical researchers
Summary
Hamilton General Hospital is a medical facility located in HAMILTON, Ontario. This center is recognized for care of Atrial Fibrillation, Thrombus, Stroke, Heart Attack, Myocardial Infarction or Heart Attack and other specialties. Hamilton General Hospital is involved with conducting 194 clinical trials across 280 conditions. There are 30 research doctors associated with this hospital, such as Principal Investigator, Jeff S Healey, MD, Maureen Meade, and Richard Whitlock, MD.Top PIs
Principal InvestigatorMAC3 years of reported clinical research
Studies Spinal fusion
Studies Emergence Delirium
8 reported clinical trials
11 drugs studied
Jeff S Healey, MDHamilton Health Sciences Centre1 year of reported clinical research
Studies Atrial Fibrillation
Studies Stroke
7 reported clinical trials
11 drugs studied
Maureen MeadeHamilton General Hospital7 years of reported clinical research
Studies Upper Gastrointestinal Bleeding
Studies Bleeding
5 reported clinical trials
11 drugs studied
Richard Whitlock, MDHamilton General Hospital2 years of reported clinical research
Studies Emergence Delirium
Studies Delirium
5 reported clinical trials
5 drugs studied
Clinical Trials running at Hamilton General Hospital
Heart Failure
Atrial Fibrillation
Coronary Artery Disease
Bleeding
Stroke
Cardiovascular Disease
Cardiotoxicity
Peripheral Artery Disease
Thromboembolism
Blood Clot
Stopping Heart Medications
for Cancer Survivors
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in \>80% of patients. Unfortunately, heart failure medications are associated with an undesirable long-term pill burden, financial costs, and side-effects (e.g., dizziness and fatigue). As a result, cancer survivors frequently ask if they can safely stop their heart failure medications once their heart function has returned to normal. Currently there is no scientific evidence in this area of Cardio-Oncology. To address this knowledge gap, the investigators have designed a randomized control trial to assess the safety of stopping heart failure medication in patients with CTRCD and recovered heart function. The investigators will enrol patients who have completed their cancer therapy and are on heart medications for their CTRCD, which has now normalized. The investigators will randomize patients with no other reasons to continue heart failure medications (e.g., kidney disease) to continuing or stopping their heart medications safely. All patients will undergo a cardiac MRI at baseline, 1 and 5 years with safety assessments at 6-8 weeks, 6 and 9 months and 3 and 5 years. The investigators will determine if stopping medications is non-inferior to continuing medications by counting the numbers of patients who develop heart dysfunction by 1 year in each group.
Recruiting3 awards Phase 4
Heart Surgery
for Coronary Artery Disease
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel/left main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). The primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel/LM CAD and ischemic left ventricular dysfunction (iLVSD). Eligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization. The secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.
Recruiting1 award N/A4 criteria
Surgical Ablation
for Atrial Fibrillation
SAFE is an international multicentre RCT of concomitant surgical atrial fibrillation (AF) ablation in patients with paroxysmal or persistent AF undergoing cardiac surgery.
Recruiting1 award N/A4 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Hamilton General Hospital?
Hamilton General Hospital is a medical facility located in HAMILTON, Ontario. This center is recognized for care of Atrial Fibrillation, Thrombus, Stroke, Heart Attack, Myocardial Infarction or Heart Attack and other specialties. Hamilton General Hospital is involved with conducting 194 clinical trials across 280 conditions. There are 30 research doctors associated with this hospital, such as Principal Investigator, Jeff S Healey, MD, Maureen Meade, and Richard Whitlock, MD.